EUCTR2011-002784-24-GB进行中（未招募）不适用
Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple versus Single Dose of Ivermectin for the Treatment of Strongyloides - STRONG TREAT 1 to 4
Sacro Cuore - Don Calabria Hospital0 个研究点目标入组 400 人开始时间: 2013年11月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male & female patients over 18 years of age.
- •- Current residence in non-endemic area (including urban areas in endemic countries)
- •- Either direct diagnosis of S. stercoralis infection (established by positive stool agar/ charcoal culture and/ or direct microscopic examination) AND positive serological test at any titre
- •- Positive serological test at 'high' titre irrespective of the results of cultures and direct tests.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Pregnant or lactating women
- •- Subjects suffering from CNS diseases
- •- Disseminated disease
- •- Immunocompromised patients (malignancies, chemotherapy or other immunosuppressive treatments).
- •- Lack of informed consent
- •- Previous treatment with Ivermectin (in the last year)
研究者
相似试验
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and tolerability of telavancin compared with standard intravenous therapy in the treatment of S. aureus bacteremiaMedDRA version: 20.0Level: LLTClassification code 10004035Term: Bacterial infection due to staphylococcus aureusSystem Organ Class: 100000004862Staphylococcus aureus Bacteremia Including Infective EndocarditisEUCTR2014-004372-27-DETheravance Biopharma Ireland Limited248
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and tolerability of telavancin compared with standard intravenous therapy in the treatment of S. aureus bacteremiaStaphylococcus aureus Bacteremia Including Infective EndocarditisMedDRA version: 19.1Level: LLTClassification code 10004035Term: Bacterial infection due to staphylococcus aureusSystem Organ Class: 100000004862EUCTR2014-004372-27-PLTheravance Biopharma Antibiotics, Inc.248
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and tolerability of telavancin compared with standard intravenous therapy in the treatment of S. aureus bacteremiaStaphylococcus aureus Bacteremia Including Infective EndocarditisMedDRA version: 19.0Level: LLTClassification code 10004035Term: Bacterial infection due to staphylococcus aureusSystem Organ Class: 100000004862EUCTR2014-004372-27-HUTheravance Biopharma Antibiotics, Inc.248
招募中
3 期
Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infective EndocarditisStaphylococcus aureus Bacteremia Including Infective EndocarditisA49.0B95.6RBR-3p8g7nInstituto Dante Pazzanese de Cardiologia
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and tolerability of telavancin compared with standard intravenous therapy in the treatment of S. aureus bacteremiaStaphylococcus aureus Bacteremia Including Infective EndocarditisMedDRA version: 19.0Level: LLTClassification code 10004035Term: Bacterial infection due to staphylococcus aureusSystem Organ Class: 100000004862EUCTR2014-004372-27-LVTheravance Biopharma Antibiotics, Inc.248